. Author manuscript; available in PMC: 2021 Sep 1.

Published in final edited form as: Int J Radiat Oncol Biol Phys. 2020 May 14;108(1):227–241. doi: 10.1016/j.ijrobp.2020.05.011

Table 2.

Preoperative IO/RT clinical trials^* in breast cancer

Sponsor/study name	Phase	N	Tumor type	Intervention
Jules Bordet Institute, Institut Curie (NCT03875573)	2	147	HR+/HER2−	SBRT ± durvalumab and oleclumab (24 Gy in 3 fractions)
Weill Medical College of Cornell University (NCT03804944)	2	100	HR+/HER2−	HT + RT (24 Gy in 3 fractions) ± FLT-3, pembrolizumab or both
Cedars-Sinai Medical Center (NCT03366844)	1	60	HR+/HER2− or TNBC	Pembrolizumab + RT (24 Gy in 3 fractions)
Columbia University (NCT02977468)	1	15	TNBC	Pembrolizumab + IORT

Abbreviations: HR+/HER2− = hormone receptor positive/human estrogen receptor 2 negative; HT = hormone therapy; IO/RT = immunotherapy/radiation therapy; IORT = intraoperative radiation therapy; RT = radiation therapy; SBRT = stereotactic body radiation therapy; TNBC = triple negative breast cancer.

Registered on clinicaltrials.gov as of April 1, 2020.